Compare Omnicom Group Inc. (OMC) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Omnicom Group Inc. vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Omnicom Group Inc. trades at $76.35 (market cap $20.54B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.35 (market cap $58.16B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 2.8× Omnicom Group Inc.'s market cap, and Omnicom Group Inc. pays the higher dividend (4.27%). Which is the better fit depends on your goals — on Pluang, investors hold Omnicom Group Inc. for 63 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days on average.
| OMC | TAK | |
|---|---|---|
Market Cap | $20.54B | $58.16B |
Volume | 1,803,209 | 2,467,530 |
Sector | Media | Health |
52-Week High | $88.94 | $19.05 |
52-Week Low | $67.27 | $13.23 |
Typical Hold Time | 63 Days | 0 Days |
Enterprise Value | $28.62B | $86.04B |
Dividend Yield | 4.27% | 3.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OMC trades at $76.45, up 1.8% on the day, with a bearish technical signal and mixed earnings history. The company reported a net loss of $54.5 million in 2025 despite revenue growth to $17.27 billion, though 2026 projections show a return to profitability. Recent news highlights leadership in digital marketing and significant new business wins, including $3.3 billion in H1 2026 billings.
The stock presents a value opportunity with a low P/S of 0.84 and a consensus price target of $104.67, implying 37% upside. However, high P/E of 202.35, recent net loss, and advertising market volatility pose risks. Analyst sentiment is cautious with 59% hold ratings, reflecting balanced near-term prospects.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
